Citations

Clear

1446 citation(s) found for "Howard, F".

Comparison of combined intravenous and intra-arterial thrombolysis with intravenous thrombolysis alone in stroke patients undergoing mechanical thrombectomy: a propensity-matched analysis
Elawady, Sameh Samir , Kasem, Rahim Abo , Mulpur, Bhageeradh , Matsukawa, Hidetoshi , Sowlat, Mohammad‐Mahdi , Orscelik, Atakan , Nawabi, Noah, Isidor, Julio , Maier, Ilko , Jabbour, Pascal , Kim, Joon‐Tae , Wolfe, Stacey Q , Rai, Ansaar, Starke, Robert M. , Psychogios, Marios‐Nikos, Yoshimura, Shinichi , Alaraj, Ali , Ezzeldin, Mohamad , Tanweer, Omar , Polifka, Adam , Siddiqui, Fazeel , Crosa, Roberto , Brinjikji, Waleed , Moss, Mark, Dağlıoğlu, Ergün , Williamson, Richard A., Kan, Peter , Chowdhry, Shakeel , Altschul, David , Spiotta, Alejandro M , Abo Kasem, Rahim , Matsukawa, Hidetoshi , Sowlat, Mohammad-Mahdi , Orscelik, Atakan , Maier, Ilko , Jabbour, Pascal , Wolfe, Stacey Quintero , Cuellar-Saenz, Hugo H , Howard, Brian M , Alaraj, Ali , Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Grandhi, Ramesh , Crosa, Roberto , Matouk, Charles , Brinjikji, Waleed , Navia, Pedro , Kan, Peter , De Leacy, Reade , Altschul, David J , Spiotta, Alejandro M , Levitt, Michael R , Cunningham, Conor M. , Jabbour, Pascal , Rai, Ansaar , Samaniego, Edgar A , Cuellar, Hugo , Alawieh, Ali , Romano, Daniele Giuseppe , Fragata, Isabel , Grandhi, Ramesh , Matouk, Charles , Park, Min S. , Williamson, Richard, Navía, Pedro , Leacy, Reade De , Levitt, Michael R. , Goyal, Nitin

Mayo Clinic

Journal of NeuroInterventional Surgery | August 23, 2024 | Volume: 17 | Issue: e2 | Pages: e261-e268

10.1136/jnis-2024-021975 | PMID 39179373 Get It

Background A combination of intravenous (IVT) or intra-arterial (IAT) thrombolysis with mechanical thrombectomy (MT) for acute ischemic stroke due to large vessel occlusion (AIS-LVO) has been investigated. However, there is limited data on patients who receive both IVT and IAT compared with IVT alone before MT. Methods STAR data from 2013 to 2023 was utilized. We performed propensity score matching between the two groups. The primary outcomes were symptomatic intracranial hemorrhage (sICH) and 90-day modified Rankin Scale (mRS) score 0–2. Secondary outcomes included successful recanalization (modified treatment in cerebral infarction (mTICI) ≥2B, ≥2C), early neurological improvement, any intracranial hemorrhage (ICH), and 90-day mortality. Results A total of 2454 AIS-LVO patients were included. Propensity matching yielded 190 well-matched patients in each group. No significant differences were observed between the groups in either ICH or sICH (odds ratio (OR): 0.80, 95% confidence interval (CI) 0.51–1.24, P=0.37; OR: 0.60, 95% CI 0.29 to 1.24, P=0.21, respectively). Rates of successful recanalization and early neurological improvement (ENI) were significantly lower in MT+IVT + IAT. mRS 0–1 and mortality were not significantly different between the two groups. However, the MT+IVT + IAT group demonstrated superior rates of good functional outcomes (90-day mRS 0–1) compared with patients in the MT+IVT group who had mTICI ≤2B, (OR: 2.18, 95% CI 1.05 to 3.99, P=0.04). Conclusion The combined use of IAT and IVT thrombolysis in AIS-LVO patients undergoing MT is safe. Although the MT+IVT+ IAT group demonstrated lower rates of recanalization and early neurological improvement, long-term functional outcomes were favorable in this group suggesting a potential delayed benefit of IAT.
The headache research priorities: Research goals from the American Headache Society and an international multistakeholder expert group
Pradhan, Amynah , Brin, Mitchell F. , Rosen, Howard J. , Lalvani, Nim, Ashina, Messoud , Phu, Thien , Digre, Kathleen B. , Russo, Andrew F. , Buse, Dawn C. , Tassorelli, Cristina, Goadsby, Peter J., Robertson, Carrie E. , Ezzati, Ali , Pradhan, Amynah A , Charles, Andrew , Ashina, Messoud , Gelfand, Amy A , Dodick, David W , Lipton, R.B. , Robertson, Carrie E , Schwedt, Todd J. , Oshinsky, Michael L. , Charles, Andrew , Burstein, Rami , Gelfand, Amy A. , Dodick, David W. , Pozo‐Rosich, Patricia , Lipton, Richard B. , Ailani, Jessica , Szperka, Christina L. , Charleston, Larry , Powers, Scott W. , Tassorelli, Cristina

Mayo Clinic

Headache: The Journal of Head and Face Pain | August 16, 2024 | Volume: 64 | Issue: 8 | Pages: 912-930

10.1111/head.14797 | PMID 39149968 Get It

Abstract Objective To identify and disseminate research priorities for the headache field that should be areas of research focus during the next 10 years. Background Establishing research priorities helps focus and synergize the work of headache investigators, allowing them to reach the most important research goals more efficiently and completely. Methods The Headache Research Priorities organizing and executive committees and working group chairs led a multistakeholder and international group of experts to develop headache research priorities. The research priorities were developed and reviewed by clinicians, scientists, people with headache, representatives from headache organizations, health‐care industry representatives, and the public. Priorities were revised and finalized after receiving feedback from members of the research priorities working groups and after a public comment period. Results Twenty‐five research priorities across eight categories were identified: human models, animal models, pathophysiology, diagnosis and management, treatment, inequities and disparities, research workforce development, and quality of life. The priorities address research models and methods, development and optimization of outcome measures and endpoints, pain and non‐pain symptoms of primary and secondary headaches, investigations into mechanisms underlying headache attacks and chronification of headache disorders, treatment optimization, research workforce recruitment, development, expansion, and support, and inequities and disparities in the headache field. The priorities are focused enough that they help to guide headache research and broad enough that they are widely applicable to multiple headache types and various research methods. Conclusions These research priorities serve as guidance for headache investigators when planning their research studies and as benchmarks by which the headache field can measure its progress over time. These priorities will need updating as research goals are met and new priorities arise.
Clinical and radiographic outcomes after mechanical thrombectomy in medium-vessel posterior cerebral artery occlusions: Subgroup analysis from STAR
Findlay, Matthew C, Maier, Ilko , Jabbour, Pascal , Kim, Joon‐Tae , Wolfe, Stacey Q , Rai, Ansaar, Starke, Robert M. , Psychogios, Marios‐Nikos , Yoshimura, Shinichi , Alaraj, Ali , Ezzeldin, Mohamad , Tanweer, Omar , Polifka, Adam , Siddiqui, Fazeel , Crosa, Roberto , Park, Min S. , Levitt, Michael R. , Brinjikji, Waleed , Moss, Mark, Dağlıoğlu, Ergün , Williamson, Richard , Navía, Pedro , Kan, Peter , Chowdhry, Shakeel , Altschul, David , Spiotta, Alejandro M , Wolfe, Stacey Quintero , Yoshimura, Shinichi , Cuellar-Saenz, Hugo H , Alaraj, Ali , Ezzeldin, Mohamad , Fragata, Isabel , Matouk, Charles , Altschul, David J , Grandhi, Ramesh , Levitt, Michael R , Crosa, Roberto , Navia, Pedro , Almallouhi, Eyad , Findlay, Matthew C. , Jabbour, Pascal , Rai, Ansaar , Shaban, Amir , Goyal, Nitin , Cuellar, Hugo , Howard, Brian M , Alawieh, Ali , Romano, Daniele G, Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Matouk, Charles , Leacy, Reade De , Grandhi, Ramesh

Mayo Clinic

Interventional Neuroradiology | August 14, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15910199241273839 | PMID 39140967 Get It

Background Whereas mechanical thrombectomy (MT) has become standard-of-care treatment for patients with salvageable brain tissue after acute stroke caused by large-vessel occlusions, the results of MT in patients with medium-vessel occlusions (MEVOs), particularly in the posterior cerebral artery (PCA), are not well known. Methods Using data from the international Stroke Thrombectomy and Aneurysm Registry (STAR), we assessed presenting characteristics and clinical outcomes for patients who underwent MT for primary occlusions in the P2 PCA segment. As a subanalysis, we compared the PCA MeVO outcomes with STAR's anterior circulation MeVO outcomes, namely middle cerebral artery (MCA) M2 and M3 segments. Results Of the 9812 patients in STAR, 43 underwent MT for isolated PCA MeVOs. The patients’ median age was 69 years (interquartile range 61–79), and 48.8% were female. The median NIH Stroke Scale score was 9 (range 6–17). After recanalization, 67.4% of patients achieved successful recanalization (modified treatment in cerebral infarction score [mTICI] ≥ 2b), with a first-pass success rate of 44.2%, and 39.6% achieved a modified Rankin score of 0–2 at 90 days. Nine patients (20.9%) had died by the 90-day follow-up. In comparison with M2 and M3 MeVOs, there were no differences in presenting characteristics among the three groups. Patients with PCA MeVOs were less likely to undergo intra-arterial thrombolysis (4.7% PCA vs. 10.1% M2 vs. 16.2% M3, p = 0.046) or to achieve successful recanalization (mTICI ≥ 2b, 67.4%, 86.7%, 82.3%, respectively, p < 0.001); however, there were no differences in the rates of successful first-pass recanalization (44.2%, 49.8%, 52.3%, respectively, p = 0.65). Conclusions We describe the STAR experience performing MT in patients with PCA MeVOs. Our analysis supports that successful first-pass recanalization can be achieved in PCA MEVOs at a rate similar to that in MCA MeVOs, although further study and possible innovation may be necessary to improve successful PCA MeVO recanalization rates.
Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer
Konda, Bhavana , Sherman, Eric J. , Morris, John C, Ryder, Mabel , Agulnik, Mark , Handley, Demond , Moses, Catherine, Jacob, Rajani, Streicher, Howard , Shah, Manisha H. , Streicher, Howard , Ryder, Mabel , Massarelli, Erminia , Nieva, Jorgé , Muzaffar, Jameel, Morris, John C, Ho, Alan L. , Wei, Lai , Moses, Catherine, Jacob, Rajani, Wright, John, Carson, William E.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | August 9, 2024 | Volume: 110 | Issue: 3 | Pages: 830-837

10.1210/clinem/dgae512 | PMID 39133806 Get It

Abstract Background This investigator-initiated phase II trial aimed to evaluate the efficacy of cabozantinib in combination with nivolumab and ipilimumab (CaboNivoIpi) in previously treated patients with radioactive iodine-refractory differentiated thyroid cancer. Methods Eligible patients with radioactive iodine-refractory differentiated thyroid cancer who progressed on 1 prior line of vascular endothelial growth factor receptor-targeted therapy received a 2-week run-in of cabozantinib monotherapy followed by CaboNivoIpi for 4 cycles (cycle length = 6 weeks), followed by cabozantinib plus nivolumab (cycle length = 4 weeks) until disease progression. The primary endpoint was objective response rate (ORR) within the first 6 months of treatment. A Simon optimal 2-stage design allowed for an interim analysis after accrual of 10 evaluable patients. At least 5 responses were needed to proceed to stage 2. Results Among 11 patients enrolled, the median age was 69 years. Prior vascular endothelial growth factor receptor-targeted therapies included lenvatinib, pazopanib, and sorafenib plus everolimus. Median follow-up was 13.4 months. Among 10 evaluable patients, ORR within the first 6 months of treatment was 10% (1 partial response). Median progression-free survival was 9 months (95% CI, 3.0–not reached) and median overall survival was 19.2 months (95% CI, 4.6–not reached). Grade 3/4 treatment-related adverse events (AEs) were noted in 55% (6/11) and grade 5 AEs in 18% (2/11) of patients. The most common treatment-related AE was hypertension. The study did not reach its prespecified efficacy threshold. Conclusion CaboNivoIpi had low ORRs and a high rate of grade ≥3 treatment-related AEs. Clinical Trial Registration NCT03914300
Baseline Normative and Test–Retest Reliability Data for Sideline Concussion Assessment Measures in Youth
Wethe, Jennifer V. , Bogle, Jamie M. , Howard, Marci, Gould, Amanda Rach, Butterfield, Richard , Buras, Matthew , Adler, Jennifer S. , Talaber, Alexandra , Soma, David , Starling, Amaal J. , Bogle, Jamie, Howard, Marci D, Buras, Matthew R , Adler, Jennifer, Starling, Amaal J , Wethe, Jennifer V , Dodick, David W.

Mayo Clinic

Diagnostics | August 1, 2024 | Volume: 14 | Issue: 15 | Pages: 1661

10.3390/diagnostics14151661 | PMID 39125537 Get It

Tools used for the identification, evaluation, and monitoring of concussion have not been sufficiently studied in youth or real-world settings. Normative and reliability data on sideline concussion assessment measures in the youth athlete population is needed. Pre-season normative data for 515 athletes (93.5% male) aged 5 to 16 on the Standardized Assessment of Concussion (SAC/SAC-Child), modified Balance Errors Scoring System (mBESS), Timed Tandem Gait (TTG), and the King–Devick Test (KDT) are provided. A total of 212 non-injured athletes repeated the measures post-season to assess test–retest reliability. Mean performance on the SAC-C, mBESS, TTG, and KDT tended to improve with age. KDT was the only measure that demonstrated good to excellent stability across age ranges (ICC = 0.758 to 0.941). Concentration was the only SAC/SAC-C subtest to demonstrate moderate test–retest stability (ICC = 0.503 to 0.706). TTG demonstrated moderate to good (ICC = 0.666 to 0.811) reliability. mBESS demonstrated poor to moderate reliability (ICC = −0.309 to 0.651). Commonly used measures of concussion vary regarding test–retest reliability in youth. The data support the use of at least annual sport concussion baseline assessments in the pediatric population to account for the evolution in performance as the child ages. Understanding the variation in the stability and the evolution of baseline performance will enable improved identification of possible injury.
A Randomized Comparison of Postprandial Glucose Excursion Using Inhaled Insulin Versus Rapid-Acting Analog Insulin in Adults With Type 1 Diabetes Using Multiple Daily Injections of Insulin or Automated Insulin Delivery
Hirsch, Irl B., Beck, Roy W. , Marak, Martin Chase , Calhoun, Peter , Mottalib, Adham , Salhin, Amna, Manessis, Anastasios , Bhargava, Anuj , Thorsell, Ashley, Atakov-Castillo, Astrid , Bode, Bruce W., Levister, Camilla, Donahue, Cassandra, Cordero, Christian, Beatson, Christie , Langel, Christine R., Jacobson, Christopher , Kurek, Corey, Cruse, Dana, Pickering, David, Tamarez, Denisa, Desjardins, Donna, O’Malley, Grenye , Aktürk, Halis Kaan , Diner, Jamie, Baran, Jesica D., Ruedy, Katrina J., Codorniz, Kevin , Klein, Klara R. , Castorino, Kristin , Jordan, L.F., Kipnes, Mark, Church, Mei Mei , Raskin, Philip, Nguyen, Quang T., Weinstock, Ruth S. , Rizvi, Shafaq, Bzdick, Suzan, Rodriguez, Tahereh Ghorbani, Salah, Tareq , Blevins, Thomas , Kudva, Yogish C. , Haider, Zehra, Group, INHALE-3 Study, Bode, Bruce W., Ownby, Jonathan G., Johnson, Joseph H., Ruiz, Adriana, Stephens, Nashia, Maxson, Amanda, Beatson, Christie, Mason, E E , Steenkamp, Devin W., Wolpert, Howard , Sullivan, Asya, Salhin, Amna, Copple, Tina, Beltran, Stephanie, Ryan, Terri, O’Malley, Grenye, Tamarez, Denisa, Ipek, Aslihan, Burke, Christine, Langel, Christine, Bauman, Shannon , Haight, Cristina, Bohr, A., Badri, Marwa Al, Nguyen, Loida, Cordero, Christian, Migliozzi, Brittney, Reid, Corey, Kaur, Ravinder Jeet , Livingood, Daine, Cruse, Dana, Kravarusic, Jelena, Coyne, Kasey, Herrmann, Stefanie, Fronczyk, Evelyn, McKillop, Lorcan, Hyatt, Jamie, Patruno, Maria, Shuirman, Maggie, Cobb, Brandon, Watt, Olivia, Casaubon, Luis, Espinosa, Valerie, Pandit, Keta, Perez, Jennifer, Armstrong, Chloe, Martinez-Arredondo, Maritza, Stewart, Ana, Rodriguez, Tahereh Ghorbani, Young, Laura , Kass, Alexander, Fulghum, Karla, Jordan, Lin, Shao, Baomei, Baran, Jesica, Mandava, Patali, Holod, Rosanna, Kaiserman, Kevin B. , Ulloa, Johanna, Pleitez, Jennifer, Sylvan, Joey, Badgett, Lynn, Borgman, Sarah, Frey, Sarah, Mba-Oduwusi, Nnenna, Miller, Paige , Fults, Ashleigh, Marak, Martin, Pritchard, Rosa, Dolzhenko, E. N. , Gabrielson, Deanna, Brown, Sue A. , Ahmann, Andrew , Bergenstal, Richard M. , Levy, Carol J , Steenkamp, Devin W , Aleppo, Grazia , Akturk, Halis K , Klein, Klara R , Castorino, Kristin , Church, Mei Mei , Hamdy, Osama , Weinstock, Ruth S , Salah, Tareq , Kudva, Yogish C. , Beck, Roy W , Calhoun, Peter , Coviello, Andrea D. , Bode, Bruce W., Levy, Carol J. , Donahue, Cassandra, Aleppo, Grazia , Buse, John B. , Nguyen, Quang T., Lee, Scott Jeffery , Group, INHALE-3 Study, Bode, Bruce W., Beatson, Christie, Mason, Emma, Steenkamp, Devin W., Salhin, Amna, O’Malley, Grenye, Bauman, Shannon, Dhaver, Shilton , Nguyen, Quang T., Cordero, Christian, Cruse, Dana, Johnson, Olivia, Rodriguez, Tahereh Ghorbani, Miller, Paige, McCarthy, Chris

Mayo Clinic

Diabetes Care | July 23, 2024 | Volume: 47 | Issue: 9 | Pages: 1682-1687

10.2337/dc24-0838 | PMID 39042575 Get It

OBJECTIVE To compare postprandial glucose excursions following a bolus with inhaled technosphere insulin (TI) or subcutaneous rapid-acting analog (RAA) insulin. RESEARCH DESIGN AND METHODS A meal challenge was completed by 122 adults with type 1 diabetes who were using multiple daily injections (MDI), a nonautomated pump, or automated insulin delivery (AID) and who were randomized to bolus with their usual RAA insulin (n = 61) or TI (n = 61). RESULTS The primary outcome, the treatment group difference in area under the curve for glucose &gt;180 mg/dL over 2 h, was less with TI versus RAA (adjusted difference −12 mg/dL, 95% CI −22 to −2, P = 0.02). With TI, the glucose excursion was smaller (P = 0.01), peak glucose lower (P = 0.01), and time to peak glucose shorter (P = 0.006). Blood glucose &lt;70 mg/dL occurred in one participant in each group. CONCLUSIONS Postmeal glucose excursion was smaller with TI than with RAA insulin in a cohort that included both AID and MDI users.
Endovascular Thrombectomy With and Without Preceding Thrombolysis in Posterior Circulation Stroke—Insights From STAR
Heide, Ev‐Christin , Brinjikji, Waleed , Chowdhry, Shakeel , Dumont, Travis M., Ernst, Marielle , Ezzeldin, Mohamad , Kan, Peter, Kim, Joon‐Tae , Moss, Mark, Polifka, Adam , Psychogios, Marios‐Nikos , Rai, Ansaar , Starke, Robert M. , Tanweer, Omar , Williamson, Richard A., Spiotta, Alejandro M , Maier, Ilko , Investigators, STAR, Kasab, Sami Al , Alawieh, Ali , Arthur, Adam Stephen , Crosa, Roberto , Cuellar, Hugo , Leacy, Reade De , Fragata, Isabel , Howard, Brian M , Jabbour, Pascal , Levitt, Michael R. , Mascitelli, Justin R , Matouk, Charles , Navía, Pedro , Osbun, Joshua W , Park, Min S. , Romano, Daniele G., Shaban, Amir , Williamson, Richard, Wolfe, Stacey Q , Yoshimura, Shinichi , Investigators, STAR

Mayo Clinic

Stroke: Vascular and Interventional Neurology | July 16, 2024 | Volume: 4 | Issue: 5 | Pages: No page available

10.1161/svin.124.001334 | PMID 41586281 Get It

Background Multiple randomized trials could not establish the noninferiority of endovascular thrombectomy (EVT) alone without preceding intravenous thrombolysis (IVT) or superiority of IVT followed by EVT in anterior circulation large‐vessel occlusion stroke. The role of prior IVT in posterior circulation large‐vessel occlusion remains controversial. Methods In this multicenter, retrospective study, patients with stroke with large‐vessel occlusion in the posterior circulation who received EVT alone or with IVT were selected from the stroke thrombectomy and aneurysm registry between 2013 and 2022. Effects of IVT followed by thrombectomy on favorable functional outcome (defined as modified Rankin scale≤3 at 90 days) and safety were investigated using multivariable logistic and linear regression models. Results Of the 588 included patients, 67% (n = 394) were treated with EVT alone and 29% (n = 170) with EVT after IVT, and 4% (n = 24) have missing values on this variable. Controlling for multiple confounding factors, IVT was not associated with a higher likelihood of favorable functional outcome at 90 days (odds ratio, 1.04 [95% CI, 0.52–2.09; P = 0.901). Thrombectomy alone did not show any safety advantages compared with those receiving IVT. Conclusion Similar functional outcomes and complication rates were seen in patients with posterior circulation large‐vessel occlusion treated with EVT alone versus EVT after IVT. Further prospective studies are required to determine the utility of IVT in posterior circulation stroke, especially in patients being directly admitted to thrombectomy centers.
Beyond Triple-Negative: High Prevalence of Quadruple-Negative Breast Cancer in African Americans
Rajack, Fareed , Esnakula, Ashwini , Naab, Tammey , Kanaan, Yasmine , Ricks‐Santi, Luisel , Oladeru, Oluwadamilola, Rajack, Fareed , Esnakula, Ashwini , Ricks-Santi, Luisel , Oladeru, Oluwadamilola T.

Mayo Clinic

Biomedicines | July 9, 2024 | Volume: 12 | Issue: 7 | Pages: 1522

10.3390/biomedicines12071522 | PMID 39062096 Get It

Quadruple-negative breast cancer (QNBC) is a triple-negative breast cancer (TNBC) subtype that lacks expression of the androgen (AR) receptor. Few studies have focused on this highly aggressive breast cancer, portending worse survival rates. We aimed to determine the following: (1) QNBC’s molecular and clinical characteristics and compare them with other subtypes and (2) QNBC’s association with clinicopathological factors and prognostic markers. We performed immunohistochemical evaluations of ARs on tissue tumor microarrays from FFPE tumor blocks of invasive ductal breast carcinomas in 202 African American women. Univariate analysis was performed using the chi-square test, with survival rates calculated using Kaplan–Meier curves. Overall, 75.8% of TNBCs were AR-negative. Compared to the luminal subtypes, TNBC and QNBC tumors were likely to be a higher grade (p < 0.001); HER2+/AR- and QNBCs were also larger than the other subtypes (p < 0.001). They also expressed increasing mean levels of proteins involved in invasion, such as CD44, fascin, and vimentin, as well as decreasing the expression of proteins involved in mammary differentiation, such as GATA3 and mammaglobin. We found no association between QNBC and stage, recurrence-free survival, or overall survival rates. The high prevalence of TNBC AR-negativity in these women could explain observed worse outcomes, supporting the existence of the unique QNBC subtype.
Efficacy and safety of fruquintinib in patients with metastatic colorectal cancer according to prior treatment sequence in the refractory setting: Results from FRESCO and FRESCO-2.
Sobrero, Alberto , García‐Alfonso, Pilar , Höchster, Howard S. , Qin, Shukui , Schelman, William R., Fan, Songhua, Yu, Ziji, Chen, Lucy F., Bekaii‐Saab, Tanios , Dasari, Arvind , Eng, Cathy , Lonardi, Sara , Yoshino, Takayuki , Yao, James C. , Bianchi, Andrea Sartore , Hubbard, Joleen M. , Price, Timothy Jay , Tougeron, David , Li, Jin , Tabernero, Josep

Mayo Clinic

Journal of Clinical Oncology | July 5, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 3579-3579

10.1200/jco.2024.42.16_suppl.3579 Get It

3579 Background: Fruquintinib (F) is a highly selective, oral tyrosine kinase inhibitor of all 3 VEGF receptors. Based on FRESCO (NCT02314819) and FRESCO-2 (NCT04322539) data, F was approved by the US FDA for previously treatedmetastatic colorectal cancer (mCRC). Efficacy and safety of F + best supportive care (BSC) vs placebo (P) + BSC were analyzed according to prior treatment (tx) sequence using FRESCO and FRESCO-2 data. Methods: In FRESCO and FRESCO-2, patients (pts) were randomized 2:1 to receive F 5 mg or matching P, PO daily x 21 days every 28 days. In FRESCO, eligible pts had received ≥2 prior chemotherapy regimens and were permitted to have received prior anti-VEGF and/or anti-EGFR therapies, whereas in FRESCO-2, in addition to standard chemotherapies, anti-VEGF, and anti-EGFR therapies if indicated, prior exposure to trifluridine/tipiracil (TAS) and/or regorafenib (rego) was required. FRESCO-2 pts must have also received a BRAF inhibitor and/or immunotherapy, if indicated and available in their country. Results: In FRESCO (F n=278 vs P n=138), no pts had received rego and 16/416 pts (4%) had received TAS. InFRESCO-2, prior therapies were balanced between F vs P arms; pts had received prior TAS or rego in these sequences: prior TAS only (n=240 vs n=121); prior rego only (n=40 vs n=18); prior rego then TAS (n=84 vs n=45); prior TAS then rego (n=95 vs n=44). Improvements in OS and PFS were seen with F vs P regardless of prior tx sequence (Table), with similar magnitudes of benefit for OS (HRs 0.53–0.77) and PFS (HRs 0.25–0.37). F safety profile was consistent regardless of prior tx sequence (Table). Conclusions: F is effective in mCRC with a manageable safety profile regardless of prior TAS or rego tx and sequence. Improvement with F was similar for OS and PFS despite the number and sequence of prior regimens. F provides a new tx option for pts with previously treated mCRC regardless of prior TAS or rego exposure. Clinical trial information: NCT04322539 . [Table: see text]
NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapyversus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repa
Lima, Caio Max Sao Pedro Rocha , Puhalla, Shannon L. , Guthrie, Katherine A. , Blanke, Charles D. , Jacobs, Samuel A., Hong, Theodore S. , Höchster, Howard S. , Overman, Michael J. , Yothers, Greg , Sanoff, Hanna K. , Cohen, Deirdre J , Henry, N. Lynn , Ganz, Patricia A. , Kopetz, Scott , Lucas, Peter C. , Wolmark, Norman , George, Thomas J.

Mayo Clinic

Journal of Clinical Oncology | June 21, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS3632-TPS3632

10.1200/jco.2024.42.16_suppl.tps3632 Get It

TPS3632 Background: Approximately 45% of dMMR/MSI-H mCRC in the immunotherapy arm progressed at 12 mos (KEYNOTE 177). We hypothesize that dMMR/MSI-H mCRC patients (pts) may be more effectively treated with the combination of PD-1/PD-L1 (PD-1) pathway blockade and mFOLFOX6/bevacizumab (bev) rather than with anti-PD-L1 therapy (atezo) alone. Preclinical work demonstrated synergistic effects between anti-PD-1/anti-VEGF as well as between oxaliplatin/anti-PD-1 in murine CRC models, and phase II data showed activity of anti-PD-1/anti-VEGF in chemotherapy refractory colon cancer. Upon AtezoTRIBE subgroup analysis of the 8 pts with dMMR mCRC treated with FOLFOXIRI+bev+atezo, median PFS was not reached, with the first pt having progression ~16 mos. Additionally, in other solid tumor malignancies, anti-PD-1 plus anti-VEGFr (i.e., HCC and RCC) as well as anti-PD-1 plus chemotherapy (i.e., gastroesophageal and lung cancers) combinations are standard first-line treatments. Methods: This two-arm prospective phase III open-label trial randomizes (1:1) mCRC dMMR/MSI-H to atezo monotherapy v mFOLFOX6/bev+atezo combination. Key inclusion criteria have been simplified on recent amendments to better mirror clinical practice for pts receiving mFOLFOX6/bev+atezo: One cycle of FOLFOX or CAPOX, with or without bev (or biosimilar) prior to enrollment allowed, dMMR tumor determined by local CLIA-certified IHC assay (MLH1/MSH2/MSH6/PMS2) or MSI-H by local CLIA-certified PCR or NGS panel; pts with total bilirubin ≤4.0 x ULN; duration of therapy for up to two years for both arms; imaging frequency on post-treatment follow-up have been reduced; as has measurable disease per RECIST. Primary endpoint is PFS. Assuming the atezo monotherapy control arm has a 48% PFS at 24 mos as assessed by site investigator, we have 80% power to detect a hazard ratio of 0.6 (equivalent to 64.4% PFS at 24 mos) with alpha 0.025 one-sided. Stratification factors include BRAFV600E status, metastatic site, and prior adjuvant CRC therapy. Secondary endpoints include overall survival, objective response rate, safety profile, disease control rate, and duration of response. Archived tumor tissue and blood samples will be collected for correlative studies. Harmonization of translational analyses is planned between GI004 (COMMIT) and A021502 (ATOMIC). Sample size has been modified with the accrual goal of 120 pts randomized between the two immunotherapy arms needed for study completion. Enrollment actively continues. Current accrual (as of 02-02-2024): 96/120. NCT02997228. Support: U10CA180868, -180822, -180888, UG1CA189867, U24CA196067; Genentech, Inc. Clinical trial information: NCT02997228 .